Showing results (61-70 of 322) with videos related to
Sort By:
Pageof 33
Blood|January 25, 2014
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II studyPaola Guglielmelli, Flavia Biamonte, Giada Rotunno, et al.Journal of Hematotherapy & Stem Cell Research|September 11, 2003
Robust levels of long-term multilineage reconstitution in the absence of stem cell self-replication in W/Wv mice transplanted with purified stem cellsAnna Rita Migliaccio, Rodolfo Lorenzini, Alessandro M Vannucchi, et al.Cancer|November 22, 2013
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyureaSrdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, et al.Blood|May 3, 2011
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progressionThorsten Klampfl, Ashot Harutyunyan, Tiina Berg, et al.British Journal of Haematology|August 19, 2014
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia veraFederico Lussana, Alessandra Carobbio, Maria L Randi, et al.Haematologica|April 5, 2015
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosisChristophe Desterke, Christophe Martinaud, Bernadette Guerton, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 30, 2002
Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cellsCristina Cellai, Anna Laurenzana, Alessandro M Vannucchi, et al.Biochemical Pharmacology|September 6, 2002
Glutathione catabolism as a signaling mechanismAldo Paolicchi, Silvia Dominici, Lisa Pieri, et al.American Journal of Hematology|June 7, 2016
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patientsPaola Guglielmelli, Giada Rotunno, Annalisa Pacilli, et al.American Journal of Hematology|December 23, 2011
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignanciesAna Puda, Jelena D Milosevic, Tiina Berg, et al.Pageof 33